Cue Biopharma, Inc., a biopharma company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells, has extended the term of the research program under its research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. Cue Biopharma entered an exclusive license and research collaboration agreement with Merck in November 2017 to dev...